Genetic Markers and Proliferative Diabetic Retinopathy

Not Applicable

Completed

• Conditions: Proliferative Diabetic Retinopathy
• Interventions: Genetic: genetic analysis

• Registration Number: NCT02879422
• Lead Sponsor: CHU de Reims

Brief Summary

Type 2 Diabetes (TD2) is the leading cause of new cases of preventable blindness in these countries (and the gold-standard treatment, laser photocoagulation has proven to be effective in preventing vision loss at the end stage of eye disease due to proliferative diabetic retinopathy (PDR) that occurs in 3 to 6 % of the cases.Therefore, the ongoing search for predictive factors of sight threatening stages of diabetic retinopathy has become more important.

Previous studies that have examined candidate predictive factors for diabetic eye disease have mostly focused on systemic risk factors leading to PDR. Among various clinical parameters, increased HbA1c % levels, uncontrolled blood pressure, diabetes duration, neuropathy and elevated triglycerides have been associated with PDR.

Some genetic factors may also account for the development of PDR and are prospectively considered in this study .

Detailed Description

In a previous study (2011), investigators demonstrated a statistically significant relation between the Endothelial Lipase(EL) c.584C\>T polymorphism and the occurrence of diabetic retinopathy in 396 french patients with diabetes type 2 (DT2) with a longitudinal follow-up.

Secondly (2014) in a subgroup of 287 DT2 patients, investigators showed the impact of the EL rare T allele was consistent with a recessive mode of inheritance, with homozygotes for the rare allele differing from the carriers of the major allele. Importantly, the homozygotes for the rare T allele were more likely to present with advanced stages of diabetic retinopathy (severe non proliferative and proliferative disease) and particularly with proliferative diabetic retinopathy (PDR).

Based on this model investigators decided to conduct a case-control prospective study comparing 155 french patients with DT2 with PDR (cases) and 155 french patients with DT2 without PDR (controls) on the basis of two genetic parameters: EL c.584C\>T polymorphism that investigators previously studied and the C(-106)T aldose reductase polymorphism widely studied in diabetic retinopathy.

Study Timeline

• Study Start: 2013-10-16
• Study First Submitted: 2016-08-22
• Study First Submitted QC: 2016-08-24
• Study First Posted: 2016-08-25
• Primary Completion: 2020-03-03
• Study Completion: 2021-01
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-10
• Last Update Posted: 2021-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 302

Inclusion Criteria

• type 2 diabetic patients
• patient with proliferative diabetic retinopathy (for arm 1)
• patient with non proliferative diabetic retinopathy (for arm 2)
• patient older than 18 years
• patient consenting to participate to the study
• patient enrolled in the national healthcare insurance program

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Diabetic patients with proliferative diabetic retinopathy	genetic analysis	-
Diabetic patients with non proliferative diabetic retinopathy	genetic analysis	-

Primary Outcome Measures

Name	Time	Method
Proliferative retinopathy diabetic	Day 0	diabetic retinopathy with a preretinal and / or prepapillary neovascularization diagnosed using ultra-wide-field imaging

Trial Locations

Locations (1)

Chu de Reims; 🇫🇷 Reims, France